The complexity cliff in natural product discovery: why full automation remains elusive and the case for collaborative intelligence.
Covering: 1992 to 2025Natural products contribute to roughly half of FDA-approved small-molecule drugs, yet their discovery has remained surprisingly resistant to the automation that has reshaped synthetic medicinal chemistry. In this review, we examine why. We propose that natural product workflows encounter a "comple...